Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing elective spine surgery involving 4 levels or less of the thoracic, lumbar, or sacral spine.~* 18 years of age and older.~Exclusion Criteria:~* Less than 40kg in weight.~* Unable to provide written, informed consent.~* History of an adverse or anaphylactoid reaction to acetylcysteine.~* Active asthma, wheezing, or using inhaled bronchodilators.~* Pregnant Women~* Known blood clotting deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dose Response Curve Placebo (Type: PLACEBO_COMPARATOR): 5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 50 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 100 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 150 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Opioid Reduction with Optimal N-acetylcysteine Dose (Type: ACTIVE_COMPARATOR): Once the optimal N-acetylcysteine dose is identified, 15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
- Placebo (Type: PLACEBO_COMPARATOR): 15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.

Based on this trial design, predict the completion outcome and termination type (if applicable).